Absci Corporation Common Stock (ABSI)

About ABSI

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-…

Sector

Health Care

Industry

Biotechnology: Commercial Physical & Biological Resarch

Employees

140

Website

www.absci.com/

Fundamentals

1-day range

$8.6$9.28

Market cap

$1.24B

P/E (trailing)

—

P/E (forward)

-12.90

EPS (trailing)

$-0.83

Dividend yield

—

Beta

2.30

Avg. volume

4.88M

Forecasts

9 analyst ratings

Absci Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• ABSI

  Absci Corporation Common Stock

  $8.72

  ▼ 7.43%
  Market cap $1.24BP/E —
  $2.24$12.06
• ONMD

  OneMedNet Corp Class A Common Stock

  $0.5801

  ▼ 0.84%
  Market cap $43.24MP/E —
  $0.49$4.22
• ISPC

  iSpecimen Inc. Common Stock

  $1.55

  ▼ 3.44%
  Market cap $3.06MP/E —
  $1.4$127.2
• CRL

  Charles River Laboratories International Inc. Common Stock

  $291.74

  ▼ 1.58%
  Market cap $11.12BP/E —
  $144.26$303.31
• ICLR

  ICON plc Ordinary Shares

  $169.84

  ▲ 0.07%
  Market cap $12.13BP/E 183.55
  $66.57$203.91
• MEDP

  Medpace Holdings Inc. Common Stock

  $599.99

  ▼ 1.89%
  Market cap $16.00BP/E 33.13
  $373$677.9
• INCY

  Incyte Corp. Common Stock

  $124.39

  ▼ 2.63%
  Market cap $24.01BP/E 15.14
  $81.09$132.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
  SeekingAlpha · 8/20/2026
• National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
  Benzinga · 8/12/2026
• Needham Reiterates Buy on Absci, Maintains $11 Price Target
  Benzinga · 8/12/2026
• BTIG Reiterates Buy on Absci, Maintains $13 Price Target
  Benzinga · 8/12/2026
• Get insights into the top gainers and losers of Tuesday's after-hours session.
  ChartMill · 8/11/2026
• Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/11/2026
• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  Benzinga · 8/11/2026
• Absci Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $318.000K Miss $1.169M Estimate
  Benzinga · 8/11/2026

• Somaratne Ransi Mudalinayake · August 3, 2026 · Grant

  383.0K
• Mary T. Szela · June 30, 2026 · Buy

  12.9K @ $11.54
• Sean McClain · June 24, 2026 · Tax Withholding

  59.9K @ $10.08
• Mary T. Szela · June 4, 2026 · Grant

  33.2K
• Mary T. Szela · June 4, 2026 · Grant

  8.4K
• Karen K. McGinnis · June 4, 2026 · Grant

  39.8K
• Karen K. McGinnis · June 4, 2026 · Grant

  10.1K
• Menelas N. Pangalos · June 4, 2026 · Grant

  39.8K
• Menelas N. Pangalos · June 4, 2026 · Grant

  10.1K
• VAN HOUTEN FRANS · June 4, 2026 · Grant

  39.8K
• VAN HOUTEN FRANS · June 4, 2026 · Grant

  10.1K
• Joseph Sirosh · June 4, 2026 · Grant

  39.8K
• Joseph Sirosh · June 4, 2026 · Grant

  10.1K
• Mary T. Szela · June 4, 2026 · Grant

  39.8K
• Mary T. Szela · June 4, 2026 · Grant

  10.1K

Institutional Ownership

March 31, 2026

Total shares held

121.41M

Total value held

$363.85M

Institutional holders

162